Associated Papers
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Diagnostic Utility of Next-Generation Sequencing in Circulating Free DNA and a Comparison With Matched Tissue in Gallbladder Carcinoma.
Mishra S et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2024
The frequency of NRAS mutation in stool samples of Iranian colorectal cancers compared to Finnish patients.
Saberi F et al.
Journal of Research in Medical Sciences : the Official Journal of Isfahan University of Medical Sciences, 2024
ConVarT: a search engine for matching human genetic variants with variants from non-human species.
Pir MS et al.
Nucleic Acids Research, 2022
The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.
Karachaliou GS et al.
Bmc Cancer, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM et al.
Pharmacological Reviews, 2022
Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ et al.
Genome Medicine, 2020
Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC).
Lohinai Z et al.
Translational Oncology, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.
Donoghue JF et al.
Cancers, 2018
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y et al.
Molecular Cancer Therapeutics, 2016
ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C et al.
Methods in Molecular Biology (clifton, N.j.), 2014
The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM et al.
Chinese Journal of Cancer, 2013
Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes.
Parker SC et al.
Plos Genetics, 2012
A growing family: adding mutated Erbb4 as a novel cancer target.
Rudloff U et al.
Cell Cycle (georgetown, Tex.), 2010
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Prickett TD et al.
Nature Genetics, 2009